Antitumor efficacy against L-1210 was expressed as a percentage of the mean survival time (MST) of the control group after measuring MST:

$$T/C = \frac{MST \text{ of the test group}}{MST \text{ of the control group}} \times 100 (%)$$

The T/C value of the compound in Example 3 at a dose of 25 mg/kg was 243% whereas the T/C value of 2'-deoxy-2'methylidenecytidine at the same dose was 152%.

We claim:

[1. A pyrimidine 2'-deoxy-2'-methylidene nucleoside compound of the formula:

wherein R¹ represents amino or hydroxy; R² represents hydrogen, halogen, a lower alkyl, a lower alkynyl or a haloalkyl; R³ and R⁴ may be the same or different and represent hydrogen, stearoyl or aminoacyl, or a pharmaceutically acceptable salt or hydrate thereof, except that both of R³ and R⁴ may not be hydrogen.

2. A compound or a pharmaceutically acceptable salt or hydrate thereof as claimed in claim 1 which is selected from the group consisting of 2'-deoxy-2'-methylidene-5'-O-stearoylcytidine and 5'-O-(2-amino-3-methylvaleryl)-2'-deoxy-2'-methylidenecytidine.]
